Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Daratumumab

Review the clinical trials studying daratumumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 35

Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial
Status: Active
Location: 699 locations
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
Status: Active
Location: 18 locations
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Status: Active
Location: 20 locations
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Status: Active
Location: 14 locations
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Status: Active
Location: 14 locations
Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) plus Daratumumab in Newly Diagnosed Multiple Melanoma Patients with Cast Nephropathy or Monoclonal Gammopathy of Renal Significance (MGRS)
Status: Active
Location: 10 locations
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Status: Active
Location: 10 locations
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Status: Active
Location: 10 locations
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
Status: Active
Location: 12 locations
Minimal Residual Disease-Guided Treatment with or Without Autologous Hematopoietic Cell Transplantation and Teclistamab for Patients with Multiple Myeloma, The MASTER-2 Trial
Status: Active
Location: 7 locations
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma, ALTITUDE Trial
Status: Active
Location: 7 locations
Teclistamab or Talquetamab in Combination with Daratumumab for the Treatment of High-Risk Smoldering Multiple Myeloma, The REVIVE Trial
Status: Active
Location: 6 locations
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Status: Active
Location: 4 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Location: 7 locations
A Study of Daratumumab
Status: Active
Location: 3 locations
Talquetamab with or without Daratumumab for the Treatment of Relapsed or Refractory Multiple Myeloma in Older Adults
Status: Active
Location: 3 locations
Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial
Status: Active
Location: 3 locations
APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma
Status: Active
Location: 3 locations
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Status: Active
Location: 4 locations
Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma
Status: Active
Location: 4 locations
Daratumumab Maintenance Therapy for Improving Survival in Patients with Light Chain Amyloidosis, EMILIA Trial
Status: Active
Location: 2 locations
Daratumumab in Combination with KRAS Vaccine and Nivolumab in Treating Refractory Pancreatic Ductal Cancer and Advanced Refractory Non-Small Cell Lung Cancer
Status: Active
Location: 2 locations
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Status: Active
Location: 3 locations
Minimal Residual Disease Response after Completing Therapeutic Drug Regimen with Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma, MILESTONE Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida